Boston Advisors LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,696 shares of the biopharmaceutical company’s stock after buying an additional 465 shares during the period. Boston Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,798,000 as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Grandfield & Dodd LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 17 shares during the last quarter. National Pension Service raised its stake in shares of Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after buying an additional 6,481 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $323,000. Princeton Capital Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 157 shares during the last quarter. Finally, CIBC World Markets Inc. raised its stake in shares of Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock valued at $8,442,000 after buying an additional 20,833 shares during the last quarter. Institutional investors own 66.79% of the company’s stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down 3.36% during mid-day trading on Tuesday, hitting $475.09. 795,446 shares of the stock traded hands. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55. The company’s 50 day moving average is $499.72 and its 200 day moving average is $420.88. The company has a market cap of $50.16 billion, a P/E ratio of 57.51 and a beta of 1.67.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. During the same quarter in the prior year, the business earned $2.57 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 9.8% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post $12.80 earnings per share for the current fiscal year.
Several equities research analysts have recently issued reports on REGN shares. Vetr lowered shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price target for the company. in a research note on Monday, May 15th. Jefferies Group LLC restated a “hold” rating and set a $357.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 12th. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Credit Suisse Group downgraded shares of Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price objective for the company. in a report on Friday, July 14th. Finally, Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and thirteen have assigned a buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $470.34.
In related news, Director Michael S. Brown sold 3,000 shares of the company’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at $1,350,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Sanofi bought 136,050 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The shares were bought at an average price of $478.17 per share, with a total value of $65,055,028.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 59,396 shares of company stock valued at $28,484,734. 10.40% of the stock is owned by company insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
